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Abstract
Baculovirus has been a common tool for protein production since the mid 1980s.
The virus has an exclusive tropism only capable of infecting the larval stages of insects.
Originally, baculovirus recombinant gene expression used Spodoptera frugiperda (Sf9) insect
cells as the host cells for protein production. However, in 1995, it was discovered that
baculoviruses could be modified to transduce mammalian cells with the insertion of a
mammalian promoter and gene of interest. Due to its ease of generation and low biology safety
hazards, this technology, known as BacMam (Baculovirus Mammalian) is popular in the research
field for protein production and for cell based and membrane binding drug discovery assays.
BacMam viruses have shown high transduction efficiencies in many widely used mammalian cell
lines such as CHO-K1, HEK293F, and U-2 OS cells. However, some cancer cell lines do not
transduce well. Because disease relevant cell lines are preferred in cell based assays, we want
to increase the transduction efficiencies in these lines. Pseudotyping, a way of modifying the
wild type envelope protein to enhance target specificity, could be a method of increasing
efficiencies. We have generated four pseudotyping viruses using the Vesicular Stomatitis Virus
glycoprotein (VSV-G).
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CHAPTER 1: Introduction

Baculovirus
The Baculoviridae are a family of rod shaped enveloped viruses whose tropism is
limited to invertebrates, mainly insects. First observed when it distressed the silk
industry in the 1500s, baculovirus technology has evolved into a major biotechnology
tool for recombinant protein expression. Its genome, composed of circular double
stranded DNA, can range anywhere between 80kb-180 kb in size45. The family is divided
into two genera: nucleopolyhedroviruses (NPVs) and granuloviruses (GVs), so named
for their morphology and their method of enveloping the nucleocapsids in infected
cells22. GVs generate occlusion bodies much smaller than those of NPVs (about 0.3 µm
in diameter and 1.5 µm respectively) and NPVs are encapsulated in polyhedrin protein
and GVs in granulin. An occlusion body is the crystalline protein matrix surrounding the
nucleocapsids of the virion. Occlusion derived viruses have evolved to protect the virus
from extinction during winter months when their hosts may die. Under normal weather
conditions, save extreme heat or UV light, they can remain viable indefinitely 38. The
crystalline matrices also can survive avian digestive systems facilitating distribution to
insect hosts15. Another difference in NPVs and GVs are their hosts, with GVs only
infecting leptidopteran (butterflies and moths) species and NPVs possessing a broader
tropism for other insects including flies and butterflies.
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The most common baculovirus utilized in our laboratory is an NPV and further
discussion will involve only NPVs. Leptidopteran infecting NPVs have been divided into
two groups of NPVs: Group I and II based on molecular phylogenies 50. NPVs can be
further subdivided by the number of nucleocapsids within the occlusion body’s virus
envelope. Those with a single nucleocapsid per envelope are called single
nucleopolyhedroviruses (SNPVs), whereas those with multiple nucleocapsids in each
envelope are called multiple nucleopolyhedroviruses (MNPVs)38. Baculoviruses are
usually named for the host that they were isolated from initially and their
classification38. For example, the Plutella xylostella nucleopolyhedrovirus (PlxyNPV) was
first observed in the Plutella xylostella (diamondback moth) and it is a SNPV. The species
of baculovirus that is used in this laboratory is the Autographa californica multiple
nucleopolyhedrovirus (AcMNPV). Found originally in Autographa californica (alfalfa
looper), it contains multiple nucleocapsids in each envelope.
Baculoviruses produce two types of virions: occluded derived (ODVs) and
budded viruses (BVs) (Figure 1). Occluded viruses (inside its crystalline matrix) initiate
viral infection while budded viruses are responsible for secondary cycles of infection.
The genome is identical, but there are key differences between the two. In Group I
NPVs, the BVs contain the glycoprotein GP64 while Group II NPVs (and also GVs) contain
the F-protein (also known as Ld130) found at one end of the virion on projections called
peplomers33,47. Glycoproteins are responsible for viral attachment and membrane
fusion entry into the host5. AcMNPV is a Group I NPV. ODVs do not contain GP64 (or Fprotein) but have their own virus encoded envelope protein, P74, without

3

peplomers26,47. ODVs obtain their envelope in the nucleus of the host cell while BVs
acquire their envelope from budding through the plasma membrane5,9. In MNPVs, ODVs
contain multiple nucleocapsids whereas BVs contain a single nucleocapsid per
envelope47.

Figure 1: Images of Budded virus and Occluded derived virus in AcMNPV. BVs contain
one nucleocapsid with GP64 protruding from peplomers at head of virion. The envelope
is derived from the host’s plasma membrane. ODVs contain multiple nucleocapsids per
envelope and are surrounded by a crystalline matrix of polyhedrin. The envelope is
derived from intranuclear microvesicles in the host’s nucleus8.
Source: http://www.microbiologybytes.com/virology/kalmakoff/baculo/baculo.html

Replication of Baculovirus in vivo
Baculoviruses have a biphasic cycle of replication where both BVs and ODVs are
produced5,22. Initial infection occurs when an insect ingests occlusion bodies (OBs)
where the polyhedra matrix is dissolved by the alkaline midgut of the host releasing
infectious ODV. ODVs infect the gut epithelial cells by direct membrane fusion20. In
several hours, infected cells become enlarged as the viral DNA replication and
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nucleocapsid assembly occurs in the nucleus4. After assembly, nucleocapsids bud in
regions where GP64 has localized on the host’s plasma membrane generating progeny
BVs which exit the basal membrane into the hemolymph of the host 22. From there, the
infection spreads primarily through the tracheal system14. In the late phase,
nucleocapsids no longer bud, but become enveloped in the host’s nucleus to create
more OBs9. Due to infection, the host dies and liquefies releasing the OBs into the
environment38. Liquefaction occurs by virus-encoded production of chitinase and
cathepsin18.
GP64
GP64 is the major glycoprotein in AcMNPV BV. It is necessary for low pH
triggered membrane fusion5. However, it has also been shown to be necessary for
budding of the nucleocapsids for propagation of BV. Knock-out gp64 (gp64-) viruses
have shown that GP64 is necessary for efficient virion budding from host’s plasma
membrane. In order to produce virus for the study, gp64- baculovirus was generated
using a stably transfected cell line supplying the GP64 protein32. Virion proliferation was
essentially eliminated in gp64- baculovirus. This indicates that cell to cell transmission
was halted due to lack of budding, not the inability to mediate membrane fusion32.
AcMNPV in biotechnology
There are many reasons that baculoviruses have become a valuable
biotechnology research tool. Because of their exclusive tropism, the biosafety
considerations of baculovirus are low and these viruses can be handled with little
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concern24. In addition, baculoviruses possess the same protein modification traits in
prokaryotic cell processing and transport systems as viruses infecting higher eukaryotic
cells22. This makes them a significant asset to research.
In nature, AcMNPVs infect insects. But in the 1970s researchers began
investigating the virus and were able to replicate the virus in vitro in insect cell lines,
particularly Trichoplusia ni (Tni) and Spodoptera frugiperda (Sf9 or Sf21) 46. For the next
decade, molecular biologists worked on modifying the viral genome. They found that it
was possible to delete the very late polyhedrin gene (with no consequences) and insert
other genes of interest to be driven by its very strong polyhedrin promoter and express
it in Tni or Sf9/Sf21 cell lines43. The deletion of the polyhedrin gene causes the
production of only BV42. In 1994, Ayers et al. published the AcMNPV genome,
beginning a new era in molecular biology and baculovirus studies2. Soon after, the
BacMid system, a site-specific transposon-mediated insertion method, was introduced
to facilitate production of recombinant protein in the AcMNPV genome27. The name
pFastBac is used to describe traditional baculovirus transfer vectors with transposon
sites. Before the BacMid system was developed, scientists had to visually select
plaques, in a virus titration, that were polyhedra negative to identify their modified
virus16. The use of baculovirus expression vectors are still widely used in academic and
industry today.
BacMam technology

6

In the mid 1990’s, two groups reported efficient transduction of mammalian
cells using a cytomegalovirus (CMV) promoter and luciferase reporter gene and using a
Rous sarcoma virus (RSV) promoter with β-galactosidase as the reporter6,19.
Hoffman et al. showed that by replacing the polyhedrin promoter with the
mammalian CMV immediate early promoter directly fused to luciferase in a baculovirus
transfer vector efficiently transduced human hepatocytes19. A baculovirus transfer
vector contains recombination sites flanking the modified region for homologous
recombination into the polyhedrin region of AcMNPV (BacMid technology)34. With
treatment of their modified baculovirus, called AcNPV-CMV, human and rabbit
hepatocytes displayed expression of luciferase showing efficient gene delivery to two
mammalian cell lines.
Boyce and Bucher excised an RSV-lacZ cassette from a holding vector and
inserted it into an AcMNPV transfer vector with additional splice and polyadenylation
sequences from simian virus 40 (SV40) to include RNA processing signals6. At the time,
RSV had already been known to show strong expression in mammalian cells.
β-galactosidase enzyme activity was used to measure transduction efficiency in various
cell lines. As with Hoffman et al., this group showed high efficiency of transduction in
human hepatocytes. However, when other human cell lines were transduced, efficiency
was low. Because cell lines expressing high and low quantities of reporter protein were
shown to internalize comparable amounts of virus, lack of expression was believed to
due to a downstream effect6. Later, another group determined that under control of the
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CAG promoter (a hybrid promoter consisting of CMV immediate early enhancer, chicken
β-actin promoter and rabbit β-globin polyadenylation sequence), many of those cell
lines were able to express the reporter protein41. These experiments also showed that
the baculovirus was not replicating in mammalian cell lines, therefore expression was
via transduction and not infection40. Soon baculovirus was able to transduce a wide
variety of mammalian cell lines. In our company, this modified baculovirus system is
now called BacMam (Baculovirus Mammalian), and will be described as such in the rest
of this manuscript to avoid confusion.
As this technology has developed it was discovered that the genome is able to
hold up to 38 kb of insert, making it possible to insert large or multiple genes into the
virus17,24. The versatility of this gene delivery tool has made it popular in the research
field for protein production and for cell based and membrane binding drug discovery
assays. BacMam transduction is often used in place of stable cell lines due to its ease of
generation, its ability to save time, as well its low biological hazards24. Production of
stable cell lines is slow, laborious, and time consuming and BacMam generation takes
considerably less time 35. In order to express two genes in a stable cell line it will take
twice the amount of time to produce the transfectant. In contrast, a co-expression of
genes using BacMams is simply a co-transduction of the two BacMam viruses together
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and is sufficient for expression of many genes in most cases (Figure 2).

Figure 2: Schematic showing co-transduction using two BacMam viruses. With
the correct ratio of each virus, it is possible to obtain cells expressing both genes X and
Y.
BacMam is generally safer than other viral vectors such as adenovirus or
lentivirus that have the ability to replicate in humans7. Because of adenovirus and
lentivirus’ infectivity, their biological safety considerations are much higher than that of
BacMam and must be handled with caution in the lab17. Also, because the polyhedrin
promoter has been deleted from the vector, these viruses are unable to replicate in
insect larvae making them environmentally safe31. For these reasons, BacMam is the
preferred method for gene expression for mammalian cells at GlaxoSmithKline.
BacMam has been proven effective in a plethora of mammalian cell types
including HEK 293(human embryonic kidney), CHO (Chinese Hamster Ovary), U2OS(human osteosarcoma)1,13,25,29, HeLa(human cervical carcinoma)13, HepG2
(hepatocytes)6,19 and Pancreatic B cells28. Some cell lines may require a higher
multiplicity of transduction (MOT) for effective transduction but they are still
transduceable. Even at a high MOT, BacMam virus is not toxic to mammalian cells,
however it has been found that high volumes of insect media(conditioned insect media
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is the preferred storage of BacMam) can be toxic to cells. This can be avoided by
concentrating virus using a sucrose cushion19. Although the effectiveness of BacMam
has been shown in many cell lines, some are more difficult to transduce. Although not
the case for all, efficiency can be enhanced in most cell lines using histone deacetylase
(HDAC) inhibitors such as trichostatin A or sodium butyrate 13. These HDAC inhibitors
cause a hyperacetylation of the chromatin for augmentation of transcription. The
markedly increased transduction can be visualized using a reporter gene BacMam such
as Green Fluorescence Protein (GFP) under control of the CMV promoter. At a
wavelength 509 nm, GFP will fluoresce demonstrating successful uptake of the virus by
the cell. Condreay et al. found that out of 20 cell lines tested, 18 were enhanced by
addition of 10 mM Sodium Butyrate 24 hours after treatment with BacMam-GFP.
However, addition of HDAC inhibitors can have a toxic effect 48. In our hands,
concentrations above 20 mM Sodium Butyrate can be significantly detrimental to most
mammalian cell lines (as shown by hemocytometer count)35. We began looking for
other ways to enhance expression in difficult to transduce cell lines.
Pseudotyping
Recently, our colleagues have been interested in using some cell lines that are
not effectively transduced by BacMam. The need is due to the physiological importance
of these lines in the diseases being investigated. For example, an Oncology team looking
for breast cancer treatments requests a screen in SKBR3, human breast adenocarcinoma
cells, a line most relevant to the disease. This is an example of a line that hasn’t been
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transduceable using BacMam with current available treatments. This led to looking into
pseudotyping BacMam virus. Pseudotyping is a general term for structural proteins
contained within a virus particle but not encoded by the viral genome39. In this case, and
most commonly, this involves introducing a foreign glycoprotein from another virus into
our original host vector. We have chosen to introduce Vesicular Stomatitis Virus
glycoprotein (VSV-G) into our BacMam vector.
VSV-G
Vesicular Stomatitis Virus (VSV) is in the family Rhabdoviridae and has tropism
for both mammalian and insect cells37. Its glycoprotein (VSV-G) is one of the most highly
used pseudotyping tools today. Originally, it was used for pseudotyping retroviruses
because of its large target range10. It has also been shown to increase Baculovirus
transduction efficiency by 10 to 100 fold greater than baculovirus without VSV-G3. In
addition to VSV’s wide tropism, it also has the capability to increase efficiency by
increasing the amount of glycoprotein on the surface of the virus envelope44. GP64 is
situated at the peplomers on the head of the virion but VSV-G is found around the
entire envelope (Figure 3).
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Figure 3: Schematic showing enhancement of glycoproteins in VSV-G pseudotyped
BacMam. Figure A shows regular virus where gp64 sits on the head of the virion and
carries GFP (green circle). Figure B shows BacMam with VSV-G which covers the virion
increasing GFP expression opportunity simply by quantity of glycoprotein.

In addition to pseudotyping using native VSV-G, it has also been found that a
truncated version containing 42 amino acids of VSV-G ectodomain (ECD) plus the
transmemembrane domain (TM) and C terminal domain (CTD) of VSV-G can effectively
increase transduction levels36. Kaikkonen et al. found an increase in efficiency of
baculovirus pseudotyped with truncated VSV-G21. Because of these observations, we
have designed a set of pseudotyping BacMams for analysis. These include the truncated
version of VSV-G and the full length version in a GFP reporter construct. In addition both
truncated and full length versions will be inserted into standard Baculovirus transfer
vectors.
Hypothesis:
Disease relevant cell lines are preferred over current cell lines due to their ability
to closely mimic in vivo conditions. BacMam transduction efficiency in these cell lines is
low. It is hypothesized that pseudotyped BacMams may deliver genes to these cell lines
more efficiently than standard BacMam.
Specific Aims:
Specifically, I will generate four different BacMam/baculoviruses that will be
used in the future to transduce disease-relevant cell lines that have historically low
transduction efficiencies:
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BacMam Vectors:
pCMVDual-ZsGreen- VSV-G truncate- BacMam vector containing both CMV
promoter driving ZsGreen, a GFP reporter protein, as well the polyhedrin promoter
driving a truncated version of VSV-G.
pCMVDual-ZsGreen- VSV-G Full Length- Same as construct above with
polyhedrin driving the Full Length VSV-G.
Baculovirus Vectors:
pFastBac-VSV-G truncate- A traditional baculovirus vector with only the insect
specific polyhedrin promoter and no reporter gene present. In this construct, polyhedrin
is driving the truncated version of VSV-G.
pFastBac-VSV-G Full Length- Same as above with polyhedrin driving Full Length
VSV-G.
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CHAPTER 2: Methods and Materials
Design of truncated VSV-G
The synthetic VSV-G was designed and ordered from the company IDT
(Coralville, IA) in the holding vector pZero2. The truncated VSV-G contained gp64 signal
sequence, a multiple cloning site, a twenty alanine spacer, and the ectodomain,
transmembrane domain and C-terminal domain of VSV-G. This was flanked by
restriction sites BamHI/XbaI to facilitate extraction of VSV-G by restriction digest.

PCR amplification of truncated VSV-G from its holding vector for pFastBac
Because of issues with the IDT product and resultant band size of cut truncated
VSV-G, PCR amplification was necessary to obtain the correct sequence from the
backbone vector pZero2. Sequence specific forward (5’ CAT CGG GCG CGG ATC CAC CAT
GGT GTC CGC CAT CGT GCT GTA CGT GCT G) and reverse (GAC TGC AGG CTC TAG ATC
ACT TGC CCA GGC GGT TCA TCT CGA TGT CGG TGT AGA TC 5’) primers were purchased
from IDT. In design, the oligos also introduced a 10 base pair homology with pFastBac (a
baculovirus transfer vector) and pCMVDual-ZsGreen (a BacMam transfer vector) for
subsequent steps in generation of final transfer vectors. In order to ensure high quality
polymerase activity, three high fidelity polymerases PFU Herculase, PFU Turbo, and PFU
Ultra, (Agilent, Santa Clara, CA) were used in the PCR amplification reaction. Forward
and reverse primers, pZero2/VSV-G (template DNA), DNTPs, PFU buffer and PFU
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polymerase were combined (one tube for each polymerase) and run in the BioRad DNA
Engine Peltier Thermal Cycler using the PCR amplification program (Settings Figure 4).
Due to the sequence homology to final vectors pCMVDual-ZsGreen and pFastBac (the
homology is the same for both vectors), the PCR product could be used for insertion of
VSV-G into the vectors.

Figure 4: PCR amplification reaction cycle

PCR amplification of VSV-G full length (FL) from its holding vector
Fortunately, the template sequence for full length VSV-G was archived in our inhouse depository. For continuity, PCR amplification was also used to isolate VSV-G FL
with PCR introduced 5’ BamHI and 3’ XbaI sites. Sequence specific forward (5’ CAT CGG
GCG CGG ATC CGC CAC CAT GAA GTG CCT TTT GTA CTT AGC CTT TTT AT) and reverse
(GAC TGC AGG CTC TAG ATT ACT TTC CAA GTC GGT TCA TCT CTA TGT CT 5’) primers
were purchased from IDT again with a 10 base homology to vector. The same
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conditions for PCR amplification were used as in the PCR for truncated VSV-G except
PFU Ultra was not used (simply out of stock), only PFU Turbo and PFU Herculase.
pCMVDual-ZsGreen preparation
The transfer vector (pCMVDual-ZsGreen) was designed in house by Jim
Fornwald. The vector contains both a polyhedrin promoter and a CMV promoter.
ZsGreen, a type of Green Fluorescence Protein (GFP), was inserted previously by Jim
Fornwald so that it was under control of the CMV promoter (Figure 5). In order to
linearize pCMVDual-ZsGreen and insert truncated and FL VSV-G under the polyhedrin
promoter, pCMVDual-ZsGreen was digested with BamHI and XbaI present in the
Multiple Cloning Site (MCS). VSV-G must be inserted under the polyhedrin promoter so
that it will not be expressed in mammalian cells which would interfere with downstream
processes. Also, VSV-G does not need to be expressed in mammalian cells; its effect is
on the virion envelope.
pFastBac preparation
The vector pFastBac was also linearized using the same restriction enzymes as
for pCMVDual-ZsGreen. pFastBac is a traditional baculovirus vector with only the insect
specific polyhedrin promoter and no reporter gene present (Figure 6). 3 µL of each
vector (each in a separate reaction) were digested with 10 units each (1 µL) of BamHI
and Xbal in the presence of 1X (4 µL) of New England BioLab’s Buffer 4 and 4ug Bovine
Serum Albumin (BSA) (4 µL). pFastBac-VSV-G (both full length and truncated) were
constructed for co-transduction purposes while pCMVDual-ZsGreen -VSV-G (both full
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length and truncated) were engineered for a single population of virus (Figure 7). In coproduction, a mixed population of virus with and without VSV-G and/or ZsGreen is
present but can sometimes be effective enough for transduction.

Figure 5: Schematic of pCMVDual-ZsGreen (provided by Jim Fornwald). The reporter
gene ZsGreen is driven by the mammalian cytomegalovirus (CMV) promoter. There is a
Multiple Cloning Site (MCS) found after the polyhedrin promoter (Ppoh) to facilitate
insertion of genes of interest. In this case, the sites BamHI and XbaI are used to insert
VSV-G sequence. AmpR (Ampicillin) and GentR (Gentamycin) antibiotic resistant
sequences are included for transformation and growing in E. coli competent cells. Tn7L
and Tn7R sites are present for BacMid production (explained later).
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Figure 6: Schematic of pFastBac (provided by GSK in-house archive). MCS is present
after Ppoh for adding genes of interest. Antibiotic resistant sites are present in the
vector as well as Tn7L and Tn7R sites.

Figure 7: Two different methods of pseudotyping. Figure A describes adding BacMam
virus with the reporter gene ZsGreen (ZSG) and Baculovirus with VSV-G ratiometrically
to Sf9 cells for production of CMVDual-ZsGreen-VSV-G Virus. This method produces a
mixed population of virus with one of either genes or both. pFastBac-VSV-G was
constructed for this. Figure B describes inserting VSV-G and CMV-ZSG into the same
transfer vector. This method produces one virus type creating a single virus population.

Inserting Truncated and Full Length VSV-G into pFastBac
The Quick Cloning Kit (BPS) was used to insert the VSV-G fragments into the
pCMVDual-ZsGreen and pFastBac vectors (Figure 8). This kit utilizes a 10 bp homology
between the fragment and the vector. 200 ng of each vector was combined with 60 ng
of fragment with 1 µL of proprietary “Buffer A”, 1 µL of “Reagent A”, and 1X BSA and
incubated at room temperature (220C) for 30 min. 1 µL of “Reagent B” added to
reaction and placed on ice for 5 min. The Quick Cloning Kit is a proprietary ligase
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independent reaction. After the reaction, the DNA was transformed into DH5alpha E.
coli competent cells and plated on LB-agar Ampicillin plates for selection. All transfer
vectors contain GentR and AmpR sites for selection and growth on antibiotic agar plates
(Figures 9-12).

Source: BPS Biosciences
Figure 8: Schematic of BPS Quick Cloning Kit Protocol. Primers include a 10 base
homology to the transfer vectors. A simple 35 min reaction with Vector, Insert, Buffer A,
Reagent A, and BSA and subsequently Reagent B in a microcentrifuge tube is sufficient
for incorporation of insert into vector.

Identification of Positive Clones
Ten colonies of each construct were run in a colony PCR for identification of
positive clones. A colony PCR uses the DNA directly from the picked colony. Reaction is
the same as PCR amplification (Figure 4) with the initial denaturation step lasting 5
minutes to lyse E. coli cells. The forward primer used for PCR was specific to the vector,
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while the reverse primer was specific to the VSV-G insert (Figure 9). Therefore, when
run on agarose gel, only positive clones will produce a band. Final constructs have
truncated or FL VSV-G in either pFastBac or pCMVDual-ZsGreen (Figures 10-13).

Figure 9: Location of Colony PCR primers. Forward primer (green) lies in the
polyhedrin promoter (exists in the vector). The reverse primer (red) is found
within insert. The PCR will only produce product if insert is present because the
reverse primer will not anneal to sequence that is not present.

Figure 10: Schematic of final construct. VSV-G truncate is under control of polyhedrin
promoter (Ppoh) and is labeled in blue. This contains gp64 short sequence (gp64SS), a
multiple cloning site (MCS) for future insertion of other sequences of interest, a 20
amino acid alanine spacer (A20) and the ectodomain, transmembrane domain, and Cterminal domain (CTD) of VSV-G. ZsGreen (labeled in green) is under the control of the
mammalian CMV promoter.
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Figure 11: pFastBac-VSV-G truncate. This construct does not contain reporter gene
ZsGreen. Truncated VSV-G has the same features as pCMVDual-ZsGreen -VSV-G
truncate.

Figure 12: pCMVDual-ZsGreen VSV-G FL. Note that there is no MCS before VSV-G in this
construct so further manipulation is not readily feasible.
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Figure 13: pFastBac VSV-G FL. Again, there is no MCS before VSV-G.

Sequencing Confirmation of Virus Transfer Vectors
Sequencing oligonucleotides were designed and ordered from IDT. Using the
electronic predicted sequence, short oligos of 24-33 bases were chosen internally and
flanking FL and Truncated VSV-G on both top and bottom strand of DNA (Table 1).
Oligos are designed every 400-500 bases for assurance of complete double strand
sequence of the insert. Sequence runs usually span between 500-800 bases. Because
the truncated VSV-G insert is only 348 base pairs in length only vector specific primers
were necessary for complete sequencing. Direct sequencing of each transfer vector was
performed by another GSK group with AB v3.1 BigDye-terminator cycle sequencing kit
(Applied Biosystems, Carlsbad, California). Each sample was amplified separately in a
cycle sequencing reaction with 1 µL AB v3.1 BigDye-terminator cycle sequencing, 6 µL of
deionized water, 1uL of DNA template, 1uL of primer and 1uL of 5X Sequencing Buffer
(Applied Biosystems) for a total volume of 10 µL. Thermal cycling conditions were one
cycle of 1 min at 96 °C, 25 cycles of 10 sec at 96 °C, 5 sec at 50 °C, 4 min at 60 °C and one
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hold of 4 °C until ready to purify. The extension products were purified using an Edge
DTR V3 96-Well Short Plate (Edge Biosystems, Gaithersburg, MD). The sequencing
reactions were analyzed using a Genetic Analyzer 3730XL (Applied Biosystems).
Primer
Name
pFB for

Strand

Sequence

Size

Use in vector

Top

CCGGATTATTCATACCGTCCCACC

24

pFB/pCMVDual

pFB rev

Bottom

CCTCTACAAATGTGGTATGGCTGATTATG

29

pFB/pCMVDual

FL VSV-G
REV 3
FL VSV-G
FOR 1
FL VSV-G
REV 2
FL VSV-G
FOR 2
FL VSV-G
REV 1
FL VSV-G
FOR 3

Bottom

GCTTGACGGGCAATAATGGTAATTAG

26

pFB/pCMVDual

FL or
truncate
FL/
truncated
FL/
truncated
FL

Top

CAGGCTTCCCTCCTCAAAGTTGTGGATATG

30

pFB/pCMVDual

FL

Bottom

GAGGTTAGAATCACATAGCCCTTTGACC

28

pFB/pCMVDual

FL

Top

GGATCTTGGATTATTCCCTCTGCCAAGAAACC

32

pFB/pCMVDual

FL

Bottom

GGTAGTTCCACTGATCATTCCGACCATTC

29

pFB/pCMVDual

FL

Top

GGTTGGTTCAGTAGTTGGAAAAGCTCTATTGCC

33

pFB/pCMVDual

FL

Table 1: List of Sequencing Oligos. They are located every 400-500 bases of the insert
on both top and bottom strands of DNA.

Generation of BacMid DNA
The BacMid system is a site-specific transposon-mediated insertion method,
used to facilitate production of recombinant DNA from the viral transfer vector into the
viral genome. After verification of desired baculovirus transfer constructs, the DNA was
transformed into DH10Bac E. coli competent cells and streaked on DH10Bac plates (LB
agar plates with 50 ug/mL Kanamycin, 10 ug/mL Tetracycline and 7 ug/mL Gentamycin)
for selection and again streaked for single colonies (Figure 14). Generation of BacMid
DNA is based on Invitrogen’s Bac-to-Bac system (Carlsbad, CA) . DH10Bac cells contain
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two types of plasmids: parent and helper. The parent plasmid contains Tn7R and Tn7L
sites for transposition of gene found in the transfer vector. Each transfer vector also
contains Tn7 sites flanking gene region (Figures 10-13) and with the assistance of the
helper plasmid, the gene is moved from transfer vector to parent. Also, found inside the
parent plasmid is the lac-Zα gene. When expressed, the protein created a blue E. coli
colony. When successful transposition occurs, this expression is disrupted creating a
white colony. This blue/white screening aids in identification of positive colonies.

Figure 14: BacMam/Baculovirus generation: The schematic shows each step of
creating a Baculovirus (or BacMam). Steps to creating virus are the same after
generation of transfer vectors. All transfer vectors contain Tn7 sites for transposition
into parent plasmid for BacMid DNA generation.
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Isolation of BacMid DNA
BacMid DNA is isolated using a modified miniprep alkaline lysis method with
reagents from Qiagen. At this point all reagents are handled using sterile work
conditions. Three large white colonies were picked for each BacMid and inoculated in 2
mL DH10Bac growth medium (LB broth with same antibiotic concentrations as DH10Bac
plates) and grown at 340C overnight. Growth was transferred to 2 mL microcentrifuge
tubes and cells were pelleted by centrifugation. Cells were resuspended with 200 µL of
reagent P1 and lysed with 200 µL P2. 200 µL of P3 was added then centrifuged for 10
minutes to pellet debris. Supernatant was collected and transferred to clean tubes.
Addition of 420 µL isopropanol precipitated BacMid DNA from supernatant. After 20
minutes in -200C, mix was centrifuged again to pellet DNA. DNA was dried and
resuspended in 50 µL of dH20.
Transfection of Sf-9 cells
Sf-9 cells were seeded into a T-25 flask at a concentration of 1x10^6 cells/mL in 3
mL. The cells were given 30 minutes to attach to the flask. Meanwhile, 25 µL of the
BacMid DNA was added to a transfection mix comprised of 200 µL EX-CELL 420 (JRH
Biosciences) media and 7 µL Fugene 6 (Roche). The mix was incubated at room
temperature for 15 min then added drop-wise directly onto the Sf-9 cells. Cells were
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incubated at 27oC overnight with 3ml of EX-CELL 420 with 10% Heat Inactivated FBS
added to the transfected cells (JRH Biosciences). The flasks were incubated for an
additional three days at 27oC before cytopathic effect occurred. Cytopathic effect is a
clearing of cells (and when held to the light, it appears as a comet like clearing). The
conditioned medium was harvested and centrifuged in a 15 mL conical tube to pellet
remaining cells. The supernatant was kept and stored at 4oC in the dark. The
supernatant is referred to as Passage 0(P0) virus.
Generation of P1 virus
The viruses were further amplified using fresh Sf-9 cells. Cells were seeded in
suspension at a concentration of 8x10^5 cells/mL in 150 mL overnight at 27oC. Cells
were infected with 1 mL of virus along with 5% heat inactivated FBS. Cells were
monitored and counted to ensure cell growth had ceased (cells usually double in 18-24
hours). When virus has infected cells, cells are lysed and growth of new cells is slowed or
ceased. Three days after infection, the cells were analyzed for viability (<50%) and
harvested in the same manner as P0 virus. The resultant P1 virus was submitted for viral
titer.
Virus Titration
Viruses were titered by Don Fisher (GSK) using Invitrogen’s BaculoTiter Assay
(Figure 15). The assay kit utilizes a stable insect cell line (Sf21) with expression of βlactamase reporter gene driven by a baculovirus-responsive promoter. Upon infection
cells show a dose-dependent response in β-lactamase activity. This activity is quantified
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by a ratiometric live-cell substrate and fluorescence that can easily be read with a
fluorescence microplate reader.

Figure 15: Schematic of BaculoTiter assay protocol. Activity is quantified on
fluorescent micro-plate reader.
Source: https://commerce.invitrogen.com/index.cfm?fuseaction=viewCatalog.
viewProductDetails&productDescription=33070
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CHAPTER 3: Results
Restriction Digest of truncated VSV-G from its holding vector
After restriction digest of pZero-2-truncated VSV-G the fragment was run on an
agarose gel for correct size identification and to separate the fragment from the pZero2
vector. After this, it was determined that the size of the fragment was double its correct
size of 360 base pairs (Figure 16).

Figure 16: First restriction digest of VSV-G cassette excised from pZero-2 using BamHI
and XbaI. Lane 1: High range ladder, Lane 2: Low range Ladder, Lanes 3&4: Restriction
digest of pZero2-VSV-G truncate. Major band is pZERO vector. Faint band is VSV-G
truncate shown at 800 bp, incorrect size (should be about 400 bp.) This is possibly
because of a dimer in the commercial vector.

PCR Amplification of truncated and Full Length VSV-G
After PCR amplification of the VSV-G truncate fragment using three different
polymerases, it was also run on a gel for size identification. This time, the fragment was
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the correct size for each reaction (Figure 17). Three polymerases were used in case one
failed, however all polymerases successfully amplified the insert and showed a
comparable concentration of DNA.

Figure 17: PCR reaction for VSV-G truncate. Two lanes for each polymerase: Lane 1: Low
range Ladder Lane 2: High range ladder. Lanes 3&4: PFU Turbo, Lanes 5&6 PFU
Herculase, Lanes 7&8: PFU Ultra. All show the correct band size for VSV-G truncate.
Also, due to the PCR, the DNA is much more concentrated for use as seen by the
brightness of the bands.

PCR amplification was used to extract FL VSV-G from its holding vector. The
expected size is 1.5 kb (Figure 18). FL VSV-G was amplified using PFU Turbo and PFU
Herculase. PFU Ultra was out of stock when performing reactions and was omitted.
Again, PFU Turbo and Herculase successfully amplified VSV-G and both with high yields.
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Figure 18: PCR amplification of VSV-G FL. Lane 1: High Range Ladder. Lane 2: Low Range
Ladder Lanes 3&4: VSV-G FL using PFU Turbo (size as expected) Lanes 6&7: VSV-G FL
using PFU Herculase (size as expected).

Restriction Digest of pFastBac and pCMVDual-ZsGreen
The transfer vectors pFastBac and pCMVDual-ZsGreen were successfully digested
with enzymes BamHI and XbaI (Figure 19). The digest of pFastBac is less concentrated
that that of pCMVDual-ZsGreen.
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Figure 19: Restriction Digest of pFastBac and pCMVDual-ZsGreen. Lane 1: High Range
Ladder. Lane 2: Low Range Ladder. Lane 3&4: Digestion of pFastBac at the correct size of
~4000 bp. Lane 5&6: Digestion of pCMVDual-ZsGreen at the correct size of ~7000 bp.

Colony PCR for pFastBac-VSV-G truncate and Full Length VSV-G
As described previously, a Colony PCR was used to identify positive clones. Of 11
colonies picked for PCR, one colony (clone 7) was a positive clone for pFastBac-VSV-G
truncate (Figure 20). Smaller bands are residual primers left from the reaction. The
colony PCR from pFastBac-VSV-G FL produced one positive clone.
The 48 colonies were picked for the colony PCR of pFastBac-VSV-G FL. Of the 48
colonies, only 1 (Colony 16) presented the correct size band (Figure 21).
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Figure 20: Colony PCR of pFastBac-VSV-G truncate. Lane 1: Low range ladder. Lanes 212: Colony PCR amplification clones. Forward insert VSV-G truncate primer and reverse
pFastBac specific primer were used to amplify regions of positive clones. Lane 6 contains
one positive clone.

Figure 21: Colony PCR of pFastBac-VSV-G FL on 48 well agarose gel. Lanes 1-24 shown.
Lane LL: Low Range ladder. Lane HL High Range Ladder. Lanes 1-24: Colonies picked for
PCR amplification. Lane 16 contains positive clone. Low bands are residual primers.

Colony PCR for pCMVDual ZsGreen-truncate VSV-G and Full Length VSV-G
The colony PCR for pCMVDual ZsGreen- VSV-G FL produced two positive colonies
as shown in Figure 22. For pCMVDual ZsGreen- VSV-G truncate, the colony PCR
produced many undesirable bands in the majority of lanes. Of the 48 colonies screened,

32

only one contained the correct size band (Figure 23). This could be due to mutations in
those colonies or mis-priming of the primers that were used for the colony PCR.

Figure 22: Colony PCR of pCMVDual-VSV-G FL. Lane 1: Low range ladder. Lanes 2-12:
Colony PCR amplification clones. Forward VSV-G specific primer and a reverse vector
specific primer were used to amplify regions of positive clones. Lanes 9 and 12 contain
positive clones.

33

Figure 23: Colony PCR of pCMVDual-VSV-G truncate on 48 well agarose gel. Lanes 1-24
shown Lanes L: Low range ladder. Lanes 1-24: Colony PCR amplification clones. Forward
VSV-G specific primer and a reverse vector specific primer were used to amplify regions
of positive clones. Lane 8: Only clone with major band at correct size indicating a
positive clone. Larger bands seen could be due to mutations or mis-priming of the
primers chosen.

At least one colony from each vector was grown and midiprepped for sequence
analysis. It was grown up in LB media with antibiotic Ampicillin for sequence analysis.
Sequencing of transfer vectors
Sequence analysis of each vector showed successful insertion of VSV-G. Figure 24
shows an example of sequence analysis of pFastBac-VSV-G truncate.
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Figure 24: Sequence Analysis of pFastBac-VSV-G truncate. Analysis shows 100% correct
sequence of the VSV-G insert. One DNA sequence read is shown to illustrate peaks in
the read.

Viral Titer of Viruses
A viral titer above 1x108 pfu/mL is acceptable at GSK for further studies. All
viruses that were produced were above that threshold and have been archived for use
of all GSK scientists. These viruses will be used to transduce cell lines that have not
expressed genes well in the past.
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Virus

Titer

Acceptable

FastBac-VSV-G truncate

1.89*10 pfu/mL

8

Yes

FastBac-VSV-G FL

1.48*10 pfu/mL

8

Yes

CMVdual-ZsGreen-VSV-G

1.46*10 pfu/mL

8

Yes

8

Yes

truncate
CMVdual-ZsGreen-VSV-G FL

3.28*10 pfu/mL

Table 2: List of Titers of Produced Viruses. All viruses possess a titer high enough for
future experiments.
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CHAPTER 4: Discussion
In conclusion, I was able to insert truncated VSV-G and FL DNA sequence into
pFastBac and pCMVDual-Zsgreen transfer vectors and create viable BacMam viruses for
expression in mammalian cells. This was confirmed by the titer of the virus. Because of
their pseudotyping elements, these BacMams should be more effective than standard
BacMam viruses.
The gene of interest VSV-G (truncated) was ordered from an outside company in
its own holding vector. After numerous attempts to isolate it with restriction enzyme
digest, it was found to be the incorrect size: exactly twice the size it should have been.
This implies that a dimer construct was delivered. Due to this, another approach had to
be used to obtain the VSV-G gene. PCR was used to amplify the gene and the product
was run on an agarose gel to extract the appropriate sized DNA.
The PCR amplification was performed using three different polymerases. With
some templates, one polymerase works better than others. It is standard practice to run
all three polymerases for those cases. As it was seen in Figures 17 and 18, the yield was
comparable and very high for each of the three polymerases.
The restriction digests of pFastBac and pCMVDual-ZsGreen show significantly
different concentrations of cut vector. The cause of this was the amount of starting
vector. pFastBac was provided at a lower concentration than pCMVDual-ZsGreen (3ul
was used in the digestion). This should have been normalized so that the starting
concentration was the same. However, the digestion was successful for both vectors.
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When the constructs that were to be generated were designed, a multiple
cloning site (MCS) was incorporated for facile insertion of other future genes of interest.
The three enzymes in the MCS were StuI/SpeI/EcoRI. This design was used for both
pCMVDual-ZsGreen and pFastBac. After successfully inserting the VSV-G synthetic gene
into these vectors, it was realized that the pCMVDual-ZsGreen vector contained the cut
sites SpeI and EcoRI internally and therefore the MCS would be unusable. The MCS for
this construct will need to be redesigned and inserted using a site directed mutagenesis
protocol. This could have been avoided by double checking the design in each construct
before starting the wet work.
In all, the BPS Quick Cloning Kit was a good approach to inserting the VSV-G
genes into the transfer vectors. However, the efficiency of the kit is typically 90% or
higher. Results for this project were 2%-16%. This is most likely due to the design of
amplification primers. The protocol suggests a 10 base homology to the vector
sequence. However, in future applications, a higher efficiency of positive clones were
observed with a vector homology of 15-18 bases.
The set of pseudotyping viruses will be used for transduction efficiency
experiments. Because of the success of VSV-G pseudotyping in retroviruses10 and other
baculoviruses3,21 reported in literature, it is anticipated that the viruses will effectively
transduce cell lines of interest. Our group has determined through literature and
personal experiences a collection of eight cell lines that have been difficult to transduce
using the standard BacMam virus approach (Table 3).
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Cell Line

Description

Reference

THP-1

Human monocyte acute Monocytic leukemia

Condreay et al. 127-32

SK-BR-3

Human Breast Adenocarcinoma

lab observance

HEPM

human embryonic palatal mesenchyme

lab observance

U937

Human monocyte histiocytic lymphoma

Condreay et al. 127-32

K562

Human lymphoblast chronic myelogenous leukemia

Condreay et al. 127-32

Raw264.7

Abelson murine leukemia virus-induced tumor macrophage

Condreay et al. 127-32

LCL-cm

B lymphocyte

Cheng et al. 1612-18

Raji

Burkitt’s lymphoma

Cheng et al. 1612-18

12

12
12
12

11
11

Table 3: Cell lines of interest. These 8 cell lines have been chosen due to literature or
lab group experiences that they do not transduce efficiently using standard BacMam
virus. They will be transduced with the pseudotyped viruses in hopes of higher gene
expression.

There are also some modifications to the VSV-G BacMam that could be done that
may increase the efficiency of transduction and targeting cancer cell lines. There are a
set of tumor homing peptides have been identified to specifically target tumor
vasculature 30. Lyp-1, F3 and CGKRK have been seen to home to the neovasculature or
lymphatics of lab created tumors. Using the MCS engineered into the BacMam transfer
vectors, we hope to insert these tumor homing peptides into the vectors for more
experiments.
If we are able to successfully transduce these cell lines, we will be able to open
another door in cancer research. With cells that are more physiologically relevant,
screening efforts may be able to bring about better compounds that can withstand
clinical trials. Attrition rates of pharmaceutical compounds are near 90% and there is a
huge need to reduce this number23. There are several ways that companies can attempt
to lower this number but more physiological in vitro primary screens may be an early
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pipeline remedy. Not only will this be helpful from a business aspect, but also for the
patients that we are hoping to treat and cure. Although this may be a small step, it
could be one step closer to curing cancer.
With more modifications, VSV-G pseudotyped BacMams could possibly be used
in the future for human gene therapy. Because BacMam viruses cannot replicate in
human cells but can transiently express genes, they would be safer than adenoviruses or
other current methods of human gene delivery. Baculoviruses have been used to
effectively treat tumors in animal models49 and perhaps could translate into a successful
model in humans.

40
Reference List

1

R. Ames, et al., "Heterologous expression of G protein-coupled receptors in U-2 OS
osteosarcoma cells," Receptors. Channels 10(3-4), 117 (2004).
Ref Type: Journal

2

M. D. Ayres, et al., "The complete DNA sequence of Autographa californica nuclear
polyhedrosis virus," Virology 202(2), 586 (1994).
Ref Type: Journal

3

J. Barsoum, et al., "Efficient transduction of mammalian cells by a recombinant
baculovirus having the vesicular stomatitis virus G glycoprotein," Hum. Gene Ther.
8(17), 2011 (1997).
Ref Type: Journal

4

G. W. Blissard and G. F. Rohrmann, "Location, sequence, transcriptional mapping, and
temporal expression of the gp64 envelope glycoprotein gene of the Orgyia
pseudotsugata multicapsid nuclear polyhedrosis virus," Virology 170(2), 537
(1989).
Ref Type: Journal

5

G. W. Blissard and J. R. Wenz, "Baculovirus gp64 envelope glycoprotein is sufficient to
mediate pH-dependent membrane fusion," J. Virol. 66(11), 6829 (1992).
Ref Type: Journal

6

F. M. Boyce and N. L. Bucher, "Baculovirus-mediated gene transfer into mammalian cells,"
Proc. Natl. Acad. Sci. U. S. A 93(6), 2348 (1996).
Ref Type: Journal

7

A. Braun, "Biosafety in handling gene transfer vectors," Curr. Protoc. Hum. Genet. Chapter
12, Unit (2006).
Ref Type: Journal

8

S. C. Braunagel, et al., "Identification and analysis of an Autographa californica nuclear
polyhedrosis virus structural protein of the occlusion-derived virus envelope:
ODV-E56," Virology 217(1), 97 (1996).
Ref Type: Journal

9

S. C. Braunagel and M. D. Summers, "Autographa californica nuclear polyhedrosis virus,
PDV, and ECV viral envelopes and nucleocapsids: structural proteins, antigens,
lipid and fatty acid profiles," Virology 202(1), 315 (1994).
Ref Type: Journal

10

J. C. Burns, et al., "Vesicular stomatitis virus G glycoprotein pseudotyped retroviral
vectors: concentration to very high titer and efficient gene transfer into
mammalian and nonmammalian cells," Proc. Natl. Acad. Sci. U. S. A 90(17), 8033

41
(1993).
Ref Type: Journal
11

T. Cheng, et al., "A rapid and efficient method to express target genes in mammalian cells
by baculovirus," World J. Gastroenterol. 10(11), 1612 (2004).
Ref Type: Journal

12

J. P. Condreay and T. A. Kost, "Baculovirus expression vectors for insect and mammalian
cells," Curr. Drug Targets. 8(10), 1126 (2007).
Ref Type: Journal

13

J. P. Condreay, et al., "Transient and stable gene expression in mammalian cells
transduced with a recombinant baculovirus vector," Proc. Natl. Acad. Sci. U. S. A
96(1), 127 (1999).
Ref Type: Journal

14

E. K. Engelhard, et al., "The insect tracheal system: a conduit for the systemic spread of
Autographa californica M nuclear polyhedrosis virus," Proc. Natl. Acad. Sci. U. S. A
91(8), 3224 (1994).
Ref Type: Journal

15

P. F. Entwistle, P. H. Adams, and H. F. Evans, "Epizootiology of a nuclear polyhedrosis virus
in European spruce sawfly (Gilpinia hercyniae): the rate of passage of infective
virus through the gut of birds during cage tests," J. Invertebr. Pathol. 31(3), 307
(1978).
Ref Type: Journal

16

W. J. Ernst, R. M. Grabherr, and H. W. Katinger, "Direct cloning into the Autographa
californica nuclear polyhedrosis virus for generation of recombinant
baculoviruses," Nucleic Acids Res. 22(14), 2855 (1994).
Ref Type: Journal

17

J. A. Fornwald, et al., "Gene expression in mammalian cells using BacMam, a modified
baculovirus system," Methods Mol. Biol. 388, 95 (2007).
Ref Type: Journal

18

R. E. Hawtin, et al., "Liquefaction of Autographa californica nucleopolyhedrovirus-infected
insects is dependent on the integrity of virus-encoded chitinase and cathepsin
genes," Virology 238(2), 243 (1997).
Ref Type: Journal

19

C. Hofmann, et al., "Efficient gene transfer into human hepatocytes by baculovirus
vectors," Proc. Natl. Acad. Sci. U. S. A 92(22), 10099 (1995).
Ref Type: Journal

20

H. M. Horton and J. P. Burand, "Saturable attachment sites for polyhedron-derived
baculovirus on insect cells and evidence for entry via direct membrane fusion," J.
Virol. 67(4), 1860 (1993).
Ref Type: Journal

42
21

M. U. Kaikkonen, et al., "Truncated vesicular stomatitis virus G protein improves
baculovirus transduction efficiency in vitro and in vivo," Gene Ther. 13(4), 304
(2006).
Ref Type: Journal

22

B. J. Kelly, L. A. King, and R. D. Possee, "Introduction to baculovirus molecular biology,"
Methods Mol. Biol. 388, 25 (2007).
Ref Type: Journal

23

I. Kola and J. Landis, "Can the pharmaceutical industry reduce attrition rates?," Nat. Rev.
Drug Discov. 3(8), 711 (2004).
Ref Type: Journal

24

T. A. Kost and J. P. Condreay, "Recombinant baculoviruses as mammalian cell genedelivery vectors," Trends Biotechnol. 20(4), 173 (2002).
Ref Type: Journal

25

T. A. Kost, J. P. Condreay, and D. L. Jarvis, "Baculovirus as versatile vectors for protein
expression in insect and mammalian cells," Nat. Biotechnol. 23(5), 567 (2005).
Ref Type: Journal

26

J. Kuzio, R. Jaques, and P. Faulkner, "Identification of p74, a gene essential for virulence of
baculovirus occlusion bodies," Virology 173(2), 759 (1989).
Ref Type: Journal

27

V. A. Luckow, et al., "Efficient generation of infectious recombinant baculoviruses by sitespecific transposon-mediated insertion of foreign genes into a baculovirus
genome propagated in Escherichia coli," J. Virol. 67(8), 4566 (1993).
Ref Type: Journal

28

L. Ma, et al., "Baculovirus-mediated gene transfer into pancreatic islet cells," Diabetes
49(12), 1986 (2000).
Ref Type: Journal

29

L. Ma, et al., "Baculovirus-mediated gene transfer into pancreatic islet cells," Diabetes
49(12), 1986 (2000).
Ref Type: Journal

30

A. R. Makela, et al., "Enhanced baculovirus-mediated transduction of human cancer cells
by tumor-homing peptides," J. Virol. 80(13), 6603 (2006).
Ref Type: Journal

31

D. R. O'Reilly, "Use of baculovirus expression vectors," Methods Mol. Biol. 62, 235 (1997).
Ref Type: Journal

32

A. G. Oomens and G. W. Blissard, "Requirement for GP64 to drive efficient budding of
Autographa californica multicapsid nucleopolyhedrovirus," Virology 254(2), 297
(1999).
Ref Type: Journal

43
33

M. N. Pearson, R. L. Russell, and G. F. Rohrmann, "Characterization of a baculovirusencoded protein that is associated with infected-cell membranes and budded
virions," Virology 291(1), 22 (2001).
Ref Type: Journal

34

R. D. Possee and L. A. King, "Baculovirus transfer vectors," Methods Mol. Biol. 388, 55
(2007).
Ref Type: Journal

35

L. Ramos, et al., "Rapid expression of recombinant proteins in modified CHO cells using
the baculovirus system," Cytotechnology 38(1-3), 37 (2002).
Ref Type: Journal

36

C. S. Robison and M. A. Whitt, "The membrane-proximal stem region of vesicular
stomatitis virus G protein confers efficient virus assembly," J. Virol. 74(5), 2239
(2000).
Ref Type: Journal

37

C. S. Robison and M. A. Whitt, "The membrane-proximal stem region of vesicular
stomatitis virus G protein confers efficient virus assembly," J. Virol. 74(5), 2239
(2000).
Ref Type: Journal

38

G. F Rohrmann, "Baculovirus Molecular Biology,"in (NCBI, Bethesda (MD) National Library
of Medicine (US), 2008).

39

D. A. Sanders, "No false start for novel pseudotyped vectors," Curr. Opin. Biotechnol.
13(5), 437 (2002).
Ref Type: Journal

40

I. Shoji, et al., "Efficient gene transfer into various mammalian cells, including non-hepatic
cells, by baculovirus vectors," J. Gen. Virol. 78 ( Pt 10), 2657 (1997).
Ref Type: Journal

41

I. Shoji, et al., "Efficient gene transfer into various mammalian cells, including non-hepatic
cells, by baculovirus vectors," J. Gen. Virol. 78 ( Pt 10), 2657 (1997).
Ref Type: Journal

42

G. E. Smith, M. J. Fraser, and M. D. Summers, "Molecular Engineering of the Autographa
californica Nuclear Polyhedrosis Virus Genome: Deletion Mutations Within the
Polyhedrin Gene," J. Virol. 46(2), 584 (1983).
Ref Type: Journal

43

G. E. Smith, M. D. Summers, and M. J. Fraser, "Production of human beta interferon in
insect cells infected with a baculovirus expression vector," Mol. Cell Biol. 3(12),
2156 (1983).
Ref Type: Journal

44
44

H. Tani, et al., "Characterization of cell-surface determinants important for baculovirus
infection," Virology 279(1), 343 (2001).
Ref Type: Journal

45

D. Theilmann, et al., "Baculoviridae,"in Virus Taxonomy: Eighth report of the International
commitee on Taxonomy of Virsuses.,(Elsevier Academic press, New York, NY,
2010), pp.177-185.

46

J. L. Vaughn, et al., "The establishment of two cell lines from the insect Spodoptera
frugiperda (Lepidoptera; Noctuidae)," In Vitro 13(4), 213 (1977).
Ref Type: Journal

47

L. E. Volkman, "Occluded and Budded Autographa californica Nuclear Polyhedrosis Virus:
Immunological Relatedness of Structural Proteins," J. Virol. 46(1), 221 (1983).
Ref Type: Journal

48

J. Wang, et al., "[Experimental study of baculovirus-mediated transfection of spiral
ganglion cells in rats]," Zhonghua Er. Bi Yan. Hou Tou. Jing. Wai Ke. Za Zhi. 42(12),
939 (2007).
Ref Type: Journal

49

S. Wang and G. Balasundaram, "Potential Cancer Gene Therapy by Baculoviral
Transduction," Curr. Gene Ther. (2010).
Ref Type: Journal

50

P. M. Zanotto, B. D. Kessing, and J. E. Maruniak, "Phylogenetic interrelationships among
baculoviruses: evolutionary rates and host associations," J. Invertebr. Pathol.
62(2), 147 (1993).
Ref Type: Journal

